Arrowhead Pharmaceuticals, INC. 8-K Filing

Ticker: ARWR · Form: 8-K · Filed: Nov 18, 2025 · CIK: 879407

Sentiment: neutral

Filing Stats: 489 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-11-18 14:49:51

Key Financial Figures

Filing Documents

01 Other Events

Item 8.01 Other Events On November 18, 2025, Arro whead Pharmaceuticals, Inc. issued a press release announcing that the U.S. Food and Drug Administration has approved REDEMPLO (plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). Arrowhead subsequently held a conference call discussing the approval. A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference. A copy of the slides presented at the conference call is attached as Exhibit 99.2 to this Current Report and incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated November 18 , 2025. 99.2 R E D E M PLO Approval Conf erence Call Nov ember 18, 2025 104 Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: November 18, 2025 ARROWHEAD PHARMACEUTICALS, INC. By: /s/ Daniel Apel Daniel Apel Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing